लोड हो रहा है...

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation

Inflammatory myofibroblastic tumor (IMT), a rare sarcoma, is primarily treated via resection of the mass. However, in cases of recurrence or unresectable tumors, no standard care exists. While crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, is only approved for non-small-cell lung cancer...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Intern Med
मुख्य लेखकों: Ogata, Misato, Hatachi, Yukimasa, Ogata, Takatsugu, Satake, Hironaga, Imai, Yukihiro, Yasui, Hisateru
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: The Japanese Society of Internal Medicine 2018
विषय:
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6478978/
https://ncbi.nlm.nih.gov/pubmed/30449794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.1640-18
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!